StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

Investment analysts at StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued on Thursday. The firm set a “hold” rating on the stock.

TherapeuticsMD Price Performance

TXMD stock opened at $1.34 on Thursday. The company’s 50 day moving average is $1.58 and its two-hundred day moving average is $1.77. TherapeuticsMD has a twelve month low of $1.15 and a twelve month high of $2.99.

Hedge Funds Weigh In On TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP lifted its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the quarter. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent quarter. Institutional investors own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.